GemPharmatech CoSHSE:688046 +5.61%95 EBITDA Margin % is 26.55% as of Mar. 2026, which is 22% below its 10-year median of 33.84. GuruFocus rates SHSE:688046 with a GF Score™ of 95/100 and a GF Value™ of ¥19.37 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 942 Biotechnology companies, GemPharmatech Co ranks better than 85.56% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. GemPharmatech Co's EBITDA for the
three
months ended in Mar. 2026 was ¥55.2 Mil. GemPharmatech Co's Revenue for the
three
months ended in Mar. 2026 was ¥208.1 Mil. Therefore, GemPharmatech Co's EBITDA margin for the quarter that ended in Mar. 2026 was 26.55%.
GemPharmatech Co (SHSE:688046) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GemPharmatech Co EBITDA Margin % Related Terms
GemPharmatech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for GemPharmatech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688046 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, GemPharmatech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GemPharmatech Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GemPharmatech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GemPharmatech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GemPharmatech Co (SHSE:688046) has a EBITDA Margin % of 26.55% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GemPharmatech Co and its competitors. This is 22% below median its historical median of 33.84. According to the industry distribution chart, GemPharmatech Co ranks #136 out of 942 companies in the Biotechnology industry, placing it in the top 14.4%.
Is GemPharmatech Co's EBITDA Margin % too high?
GemPharmatech Co's current EBITDA Margin % of 26.55% is 22% below median its 10-year median of 33.84. Based on the distribution chart, GemPharmatech Co ranks #136 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GemPharmatech Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GemPharmatech Co ranks #136 out of 942 companies for EBITDA Margin %. This places GemPharmatech Co in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GemPharmatech Co and its competitors. GemPharmatech Co's current EBITDA Margin % is 26.55%, which is 22% below median its own 10-year median of 33.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥19.37, compared to a current price of ¥24.08 — trading 24.3% above its estimated fair value. The current EBITDA Margin % is 26.55%, which is 22% below median its 10-year median of 33.84. GemPharmatech Co's overall GF Score™ is 95/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current EBITDA Margin % is 26.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?
Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued.
The current stock price of ¥24.08 is trading 24.3% above its estimated GF Value™ of ¥19.37.
GuruFocus considers GemPharmatech Co to be Modestly Overvalued.
Key valuation signals for SHSE:688046:
EBITDA Margin %: 26.55% (22% below median its 10-year median of 33.84)
GF Value™: ¥19.37 vs. price of ¥24.08 (24.3% above fair value)
No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
95GF Score
Get the complete analysis for SHSE:688046
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688046 has been successfully added to your 
